Population	Secondary prevention patients who have suffered a CHD event or a stroke (cohort weighted 57.9% post-CHD and 42.1% post-stroke)
Intervention	Polypill strategy (ASA, atorvastatin, ramipril)
Comparators	Same monocomponents administered concomitantlya
Model structure	Markov model with 4 health states Stable Acute CHD Acute stroke Death state (CV death, non-CV death) Annual cycles (except for the first year with 3-month cycle length)
Model setting	Payer perspective of the Portuguese National Healthcare Service Lifetime horizon Discount rate (costs and health outcomes): 4%
CV risk equations	SMART risk equations for recurrent CHD and stroke risk model (Dorreijstein et al[@161319]) for the base case Framingham risk equations for the sensitivity analysis D’Agostino et al[@161320] for subsequent CHD risk model D’Agostino et al[@161321] for primary stroke risk model
Outcomes	Health outcomes: LY gained QALY gained No. of subsequent CV events, recurrent strokes, and CV deaths prevented by using the polypill strategy vs monocomponents Cost outcomes: Total costs Incremental results ICER with polypill strategy vs monocomponents ICUR with polypill strategy vs monocomponents